28 results
Thalassemia - Electrophoresis - Comparison Table
In this disorder it is the defective production of hemoglobin that
Electrophoresis - Comparison Table ... Hemoglobin E - MCV ... Beta #Comparison #Table ... #Hematology #Electrophoresis
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
distinction has HUGE treatment ... and first-line treatment ... Comparison #Diagnosis #Table ... #Hematology
Thromboelastogram Interpretation
Reaction Time (R Value):
 - Time till initiation of fibrin clot
 - Treatment: FFP, protamine
K
fibrin clot - Treatment ... interaction - Treatment ... minutes after MA/MCF ... - Treatment: ... #coagulation #hematology
Selected Treatments for Hip Fracture. Panel A shows internal fixation with multiple screws for a nondisplaced
Selected Treatments ... screw for the treatment ... recommended for stable ... InternalFixation #NEJM
Myositis Specific Antibodies (MSAs)

Dermatomyositis: MDA5, TIF1y, NXP2, Mi-2, SAE
Anti-Synthetase Syndrome: Jo-1, PL7, PL12, EJ, OJ
Immune Mediated
, TIF1y, NXP2, Mi ... clinical #diagnosis #rheumatology ... #table
Autoantibodies in Rheumatology
 • Lupus (SLE): ANA (anti-nuclear antibody), dsDNA (double-stranded DNA), Anti-Smith, Anti-Ro (SSA) and
Autoantibodies in Rheumatology ... , Others: SRP, Mi ... Autoantibodies #Rheumatology ... #associations #table
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#pharmacology #treatment ... #medications #table ... decisionaid #cardiology #hematology
Optic Neuritis - Diagnosis and Management
 • Epidemiology: Female (75%), 18-50 years,
caucasian
 • Symptoms: Moderate visual
R-G or B-Y • MRI ... corticosteroids TREATMENT ... Diagnosis #Management #treatment ... #rheumatology #
Inflammatory Myopathies
Dermatomyositis
 • Onset: Subacute
 • Pattern: Proximal
 • CK: Up to 50X ULN
 • Autoantibodies:
Anti-MDA5, anti-Mi ... diagnosis #comparison #rheumatology ... #table
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology ... diagnosis #comparison #table